Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Advanced Solid Tumors 169Advanced Solid Tumor 150Solid Tumor 126Mesothelioma 86Mesothelioma, Malignant 80Solid Tumors 77Hematopoietic and Lymphatic System Neoplasm 47Solid Tumor, Adult 35Carcinoma, Non-Small-Cell Lung 32Retinoblastoma 29Ovarian Neoplasms 26Melanoma 24Colorectal Neoplasms 21Pancreatic Neoplasms 20Stomach Neoplasms 19Sarcoma 18Lung Neoplasms 18Carcinoma, Renal Cell 18Uterine Cervical Neoplasms 15Malignant Solid Neoplasm 15Esophageal Neoplasms 15Neoplasms 14Neoplasm Metastasis 14Hematopoietic and Lymphoid System Neoplasm 14Triple Negative Breast Neoplasms 13Solid Tumor Malignancies 13Small Cell Lung Carcinoma 13Advanced or Metastatic Solid Tumors 13Advanced Malignant Solid Tumor 13Squamous Cell Carcinoma of Head and Neck 12

Interventions

Leflunomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer × Other solid neoplasm × 1 year × Clear all
NCT04997993 2025-06-25

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 1 Recruiting
24 enrolled
BreastOther solid neoplasm

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡